What Will Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Be Like After It Drops -69.71% From Its Highs?

During the recent session, Kala Pharmaceuticals, Inc. (NASDAQ:KALA)’s traded shares were 1,977,094, with the beta value of the company hitting 0.42. At the last check, the stock’s price was $8.65, reflecting an intraday gain of 5.38% or $0.44. The 52-week high for the KALA share is $14.68, that puts it down -69.71% from that peak though still a striking +41.73% gain since the share price plummeted to a 52-week low of $5.04. The company’s market capitalization is $482.25 Million, and the average intraday trading volume over the past 10 days was 2.48 Million shares, and the average trade volume was 1.79 Million shares over the past three months.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Kala Pharmaceuticals, Inc. (KALA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.7. KALA has a Sell rating from none of the analyst(s) out of 7 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while none of them suggest Overweight, and 6 recommend a Buy rating for it. None of the analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.46.

Kala Pharmaceuticals, Inc. (KALA) registered a 5.38% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 2.91% in intraday trading to $8.94- this Wednesday, Feb 03, hitting a weekly high. The stock’s 5-day price performance is 12.14%, and it has moved by 28.02% in 30 days. Based on these gigs, the overall price performance for the year is 28.02%. The short interest in Kala Pharmaceuticals, Inc. (NASDAQ:KALA) is 8.92 Million shares and it means that shorts have 4.98 day(s) to cover.

The consensus price target of analysts on Wall Street is $20.86, which implies an increase of 141.16% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $10 and $49 respectively. As a result, KALA is trading at a discount of 466.47% off the target high and 15.61% off the low.

Kala Pharmaceuticals, Inc. (KALA) projections and forecasts

Statistics show that Kala Pharmaceuticals, Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Kala Pharmaceuticals, Inc. (KALA) shares have jump down -11.43% during the last six months, with a year-to-date growth rate more than the industry average at 30.07% against 14.3%. Yet analysts are ramping up their growth forecast for the fiscal year 2021. Revenue is predicted to grow 27% this quarter and then jump 9.3% in the quarter after that. In the rating firms’ projections, revenue will increase 5.9% compared to the previous financial year.

Revenue for the current quarter is expected to be $2.39 Million as predicted by 6 analyst(s). Meanwhile, a consensus of 3 analyst(s) estimates revenue growth to $5Million by the end of March 2021. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $1.18 Million and $1.07 Million respectively. In this case, analysts expect current quarter sales to grow by 102.5% and then jump by 366.9% in the coming quarter.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings fell an estimated -27.1%. While earnings are projected to return -10.6% in 2021, the next five years will return 0% per annum.


A Backdoor Way To Profit From Today’s Crypto Bull Market

Even if you’re not actively in crypto, you deserve to know what’s actually going on…

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.

Sponsored


Kala Pharmaceuticals, Inc. (NASDAQ:KALA)’s Biggest Investors

Kala Pharmaceuticals, Inc. insiders own 1.01% of total outstanding shares while institutional holders control 81.46%, with the float percentage being 82.29%. RA Capital Management, L.P. is the largest shareholder of the company, while 171 institutions own stock in it. As of Sep 29, 2020, the company held over 10.87 Million shares (or 19.39% of all shares), a total value of $81.56 Million in shares.

The next largest institutional holding, with 5.47 Million shares, is of Orbimed Advisors LLC.’s that is approximately 9.75% of outstanding shares. At the market price on Sep 29, 2020, these shares were valued at $40.99 Million.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Also, the Mutual Funds coming in first place with the largest holdings of Kala Pharmaceuticals, Inc. (KALA) shares are Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund and Vanguard Total Stock Market Index Fund. Data provided on Sep 29, 2020 indicates that Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund owns about 3,450,000 shares. This amounts to just over 6.15 percent of the company’s overall shares, with a $25.88 Million market value. The same data shows that the other fund manager holds slightly less at 1.02 Million, or about 1.82% of the stock, which is worth about $7.64 Million.

Latest posts